Age- and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in Taiwan by Wang, Wuan-Szu et al.
RESEARCH ARTICLE Open Access
Age- and gender-specific population attributable
risks of metabolic disorders on all-cause and
cardiovascular mortality in Taiwan
Wuan-Szu Wang
1, Mark L Wahlqvist
2, Chih-Cheng Hsu
2, Hsing-Yi Chang
2, Wan-Chi Chang
1 and Chu-Chih Chen
1*
Abstract
Background: The extent of attributable risks of metabolic syndrome (MetS) and its components on mortality
remains unclear, especially with respect to age and gender. We aimed to assess the age- and gender-specific
population attributable risks (PARs) for cardiovascular disease (CVD)-related mortality and all-cause mortality for
public health planning.
Methods: A total of 2,092 men and 2,197 women 30 years of age and older, who were included in the 2002
Taiwan Survey of Hypertension, Hyperglycemia, and Hyperlipidemia (TwSHHH), were linked to national death
certificates acquired through December 31, 2009. Cox proportional hazard models were used to calculate adjusted
hazard ratios and PARs for mortality, with a median follow-up of 7.7 years.
Results: The respective PAR percentages of MetS for all-cause and CVD-related mortality were 11.6 and 39.2 in
men, respectively, and 18.6 and 44.4 in women, respectively. Central obesity had the highest PAR for CVD mortality
in women (57.5%), whereas arterial hypertension had the highest PAR in men (57.5%). For all-cause mortality,
younger men and post-menopausal women had higher PARs related to Mets and its components; for CVD
mortality, post-menopausal women had higher overall PARs than their pre-menopausal counterparts.
Conclusions: MetS has a limited application to the PAR for all-cause mortality, especially in men; its PAR for CVD
mortality is more evident. For CVD mortality, MetS components have higher PARs than MetS itself, especially
hypertension in men and waist circumference in post-menopausal women. In addition, PARs for diabetes mellitus
and low HDL-cholesterol may exceed 20%. We suggest differential control of risk factors in different subpopulation
as a strategy to prevent CVD-related mortality.
Background
Metabolic disorders such as arterial hypertension (AH),
hypercholesterolemia, diabetes mellitus (DM), high tri-
glycerides (TG), abdominal obesity, and metabolic syn-
drome (MetS) are associated with cardiovascular disease
(CVD) and CVD-related mortality. Furthermore, meta-
bolic disorders and MetS have contributed to all-cause
mortality in U.S., European, Australian, and Asian popu-
lations [1-8]. Given the global public health burden of
metabolic disorders, the corresponding metabolic risk
factors warrant more careful examination to develop
prevention strategies for various subpopulations.
The prevalence of MetS and metabolic disorders, as
well as their associations with morbidity and mortality,
vary according to gender, age, and ethnicity [3,8-12].
The age-related increase in CVD in women tends to be
delayed compared to men and is often delayed until the
post-menopausal period. These differences lead to dif-
ferences in the risk factor associations for the gender-
age interaction [11,13,14]. Although the prevalence of
MetS increases with age, its association with mortality
i no l d e ra d u l t si sn o ta ss i g n i f i c a n ta si nt h em i d d l e -
aged population [10,15].
Significant associations between metabolic disorders
and MetS and CVD mortality, as well as all-cause mor-
tality, have been demonstrated in Asian populations
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corresponding population attributable risks (PARs) of
these factors [5]. From a preventive perspective, PARs
are a helpful measurement for planning public health
interventions and creating new public policy. As such, it
should be recalculated periodically [4,16], especially for
individual risk factors in different subgroups. The aim of
this study was to assess the age and gender effects of
MetS and metabolic disorders, including high waist cir-
cumference (WC), AH, DM, high TG, and low high-
density lipoprotein cholesterol (HDL-C) on all-cause
and CVD-related mortality within an 8-year follow-up
period.
Methods
Study population and mortality data
The study subjects were identified from the 2002 Taiwan
Survey of Hypertension, Hyperglycemia, and Hyperlipide-
mia (2002 TwSHHH) [17-20], a cross-sectional study that
followed the 2001 National Health Interview Survey
(NHIS) of Taiwan. The 2001 NHIS was an island-wide
health survey. Non-institutionalized households were
selected through a multistage, stratified, systematic sam-
pling design, with the numbers of sampling units propor-
tional to the background population of each stratum
(e.g., an administration district such as a county or a
city). Half of the primary sampling units of the 2001
NHIS were selected, and all household members older
than 15 years were interviewed for the 2002 TwSHHH
study. Residents in military housing communities, medi-
cal facilities, schools, job training centers, dormitories,
prisons, or offshore islands were excluded from the
study. The subjects were linked to the National Death
Registry, which includes mortality data from March 3,
2002 to December 31, 2009 and lists causes of death as
defined in accordance with the International Classifica-
tion of Diseases, ninth revision (ICD-9) [21]. A total of
2,092 men and 2,197 women aged 30 years and older
were evaluated for associations between obesity-related
metabolic risk factors and mortality during an 8-year fol-
low-up period. There were 74 deaths in total. These
deaths had ICD-9 codes of 250 (17 cases of DM, 23%);
390-398 (1 case of acute rheumatic fever and chronic
rheumatic heart disease, 1.4%); 401 (5 cases of essential
hypertension, 6.8%); 402 (1 cases of hypertensive heart
disease, 1.4%); 410-414 and 429.2 (12 cases of ischemic
heart diseases and unspecified CVD, 16.2%); 415-417,
424-427, and 429 (7 cases of diseases of the pulmonary
circulation and all other forms of heart diseases, 9.5%);
428 (2 cases of heart failure, 2.7%); 430-438 (27 cases of
cerebrovascular diseases, 36.5%); 440 (1 case of athero-
sclerosis, 1.4%); and 441 (1 case of aortic aneurysm and
dissection, 1.4%). Participants with no death registry
record were assumed to be alive for the entire study
period. The median length of follow-up was 7.7 years.
Because accidental deaths, such as motor vehicle colli-
sions, suicide, and homicide, were unrelated to MetS,
these deaths were excluded from the analyses. The Insti-
tutional Review Board of the National Health Research
Institutes of Taiwan approved this study.
Measurements and definition of obesity-related metabolic
disorders
The results of the anthropometric measurements, blood
pressure measurements, and blood sample analyses have
been reported previously [17]. Central obesity was
defined as a WC ≥ 90 cm in men and ≥ 80 cm in women.
AH was defined as an average systolic blood pressure
(SBP) of ≥ 140 mmHg, a diastolic blood pressure (DBP)
of ≥ 90 mmHg, or treatment for previously diagnosed
hypertension. DM was defined as a fasting plasma glu-
cose (FPG) concentration ≥ 126 mg/dL (7 mmol/L) or
the use of insulin or other hypoglycemic agents. High TG
was defined as a serum triacylglycerol concentration ≥
200 mg/dL (2.26 mmol/L). Low HDL-C was defined as a
HDL-C < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/
dL (1.29 mmol/L) in women. MetS was defined using the
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATP III) clinical guideline (modi-
fied for Asian populations), which require the presence
of at least three characteristics: 1. WC ≥ 90 cm in men
and ≥ 80 cm in women (21); 2. SBP ≥ 130 mmHg, DBP ≥
85 mmHg, or self-reported treatment with antihyperten-
s i v em e d i c a t i o n s ;3 .F P G≥ 110 mg/dL (6.1 mmol/L) or
the use of insulin or hypoglycemic agents; 4. HDL-C < 40
mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.29
mmol/L) in women; and 5. serum TG ≥ 150 mg/dL (1.7
mmol/L) [22]. Instead of using the definition from the
International Diabetes Federation Chinese, which was
developed for diabetes, we adopted the modified MetS
definition from ATP III, which was officially recom-
mended by Taiwan’s Department of Health (DOH) [23].
Statistical analysis
A Cox proportional hazard model was fitted using the
SAS procedure “PROC PHREG” (SAS Institute, Cary,
N C ,U S A )t oe s t i m a t et h em o r t ality hazard ratios (HRs)
predicted by the individual metabolic disorders and
MetS, using data analyzed through December 31, 2009,
the last day of follow-up. Adjusted HRs were obtained by
accounting for potential confounding variables: age (30-
45, 45-55, and ≥ 55 years old), coronary artery disease
(CAD), stroke, BMI (< 18.5, 18.5-24, 24-27, and > 27),
personal behaviors (smoking, alcohol drinking, betel nut
chewing, and exercising), and socioeconomic status
(income). CAD and stroke were defined as having a self-
reported history of CAD or stroke before the survey. The
BMI cutoffs were adopted by Taiwan’s DOH for obesity
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the cutoffs recommended by the World Health Organiza-
tion (WHO). Smoking was defined as ever having
smoked for more than 100 cigarettes. Alcohol drinking,
betel nut chewing, and exercise were defined as currently
having the respective behavior. Socioeconomic status was
classified as no income, low income (less than 10,000
New Taiwan Dollars [NTDs]), secondary low income
(10,000 to 40,000 NTDs), and medium income (greater
than 40,000 NTDs). Pearson Chi-squared statistics were
employed to test for gender differences. A Kaplan-Meier
analysis (SAS procedure “PROC LIFETEST”) was used to
estimate the cumulative probability of the survival curves
for all-cause and CVD-related mortality. Log-rank tests
were used to test for subgroup differences. The signifi-
cance level was set to p < 0.05.
To assess the contribution of the individual metabolic
risk factors, PARs were calculated using the following
equation [16]:
PAR = pd(HR − 1)/HR (1)
where pd is the proportion of disease-specific exposure
to the given risk factor among total deaths, and HR is the
adjusted hazard ratio obtained from the Cox regression
model. To avoid unstable estimates due to a low mortality
rate, the bootstrap method was employed to generate 95%
confidence intervals (CI) for the PARs by taking the 2.5
and 97.5 percentiles among 1000 re-sampled datasets
using the SAS procedure “PROC SURVEYSELECT”. Sub-
group analyses for the HRs and PARs of the metabolic risk
factors for all-cause and CVD-related mortalities were per-
formed for women and men separately. In addition to stra-
tifying the groups by gender, the subjects were further
divided by age (30-45, 45-55, and ≥ 55 years old). Addi-
tionally, women were stratified by menopausal status
(45-55, and ≥ 55 years) and analyzed separately from men.
Results
Baseline characteristics
Table 1 summarizes the baseline characteristics and preva-
lence of obesity-related metabolic disorders of the 2,092
men and 2,197 women who participated in the study. The
numbers and percentages of all-cause and CVD-related
deaths for each variable category are also listed. There
were significant gender differences in age, BMI, alcohol
drinking, smoking, betel nut chewing, exercise, education
level, marital status, and income (p < 0.05). Men were sub-
stantially more likely to drink alcohol, smoke, and chew
betel nuts than women. The prevalence of MetS, AH, DM,
and elevated TG was also higher in men.
During the 32,173 person-years of follow-up, there
were 258 all-cause (167 men and 91 women) and 74
CVD-related deaths (42 men and 32 women). Figure 1
shows the prevalence of MetS stratified by age and gen-
der. The MetS prevalence increased with age for both
men and women. Men had higher MetS prevalence and
CVD deaths than women before age 60. However, the
gender difference in prevalence reversed after age 60
(men 30.4%, women 40.3%). The proportions of CVD-
related deaths among these MetS subjects had similar
trend for both genders, with the death rate increased
substantially for women aged over 60.
Gender and age-specific HRs and PARs
Table 2 lists the gender-specific crude and adjusted HRs
and PARs by risk factor for all-cause and CVD-related
deaths after controlling for age, BMI, self-reported CAD,
stroke, and personal health behaviors such as smoking,
alcohol drinking, betel nut chewing, and exercise. For all-
cause mortality, AH had the highest HR (95% CI) for both
men (1.88, 1.36-2.67) and women (2.19, 1.41-3.88). The
association of MetS with all-cause mortality was mediocre
in both genders, with HRs of 1.50 (1.03-2.19) in men and
1.77 (1.08-2.89) in women. DM and low HDL-C were also
associated with all-cause mortality in men, with HRs of
1.70 (1.12-2.65) and 1.72 (1.22-2.52), respectively. The
PARs of these risk factors ranged from 12.6% (4.5-21.8%)
for low HDL-C to 26.4% (13.2-38.8%) for AH in men and
29.9% (13.5-47.5%) for AH in women.
For CVD-related mortality, the respective associations
of MetS, DM, and low HDL-C were even stronger, with
adjusted HRs of 3.19 (1.55-7.58), 3.39 (1.51-8.61) and
2.07 (0.88-4.63) in men, respectively, and 3.45 (1.67-
8.83), 2.38 (0.98-5.70), and 2.69 (1.25-6.51) in women,
respectively. The respective associated PARs (%) of the
MetS, DM, and low HDL-C were 39.2 (15.4-62.5), 26.8
(8.3-48.5), and 18.4 (3.0-38.9) in men, respectively, and
44.4 (18.7-69.8), 19.9 (3.4-42.3), and 33.4 (9.0-59.7) in
women, respectively. While AH had the highest HR
(4.07, 1.84-9.98) and PAR (57.5%, 28.6-79.6%) in men,
central obesity was not a significant risk factor. In con-
trast, high WC was the strongest risk factor for women
with a HR of 3.78 (1.79-13.6) and a PAR of 57.5% (29.3-
84.3%). Of the CVD-related deaths, 8 out of 74 had ICD-
9 codes of 415-417, 424-427, 429, and 441, which may
not have been directly related to CVD mortality. We re-
analyzed our results after excluding these cases and
obtained very similar outcomes (data not shown).
Figure 2 shows the effects of age on the PARs of the
risk factors for all-cause mortality. Younger men (30-45
years old) had higher PARs except for high WC. In con-
trast, older women (≥ 55 years old) had higher PARs
than their younger counterparts. The PAR scales of
MetS, high WC, and AH were also different in men and
women across different age categories. Because smoking
was much more prevalent in men than women (53.4% vs.
3.9%), the PAR of smoking was shown as a risk factor in
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Characteristics (%) Men (n =
2092)
Death Women (n = 2197) Death p-
value
c
All-cause (n =
167)
CVD (n = 42) All-cause (n = 91) CVD (n = 32)
Age (yrs.) 0.0001
30-45 920 (44.0) 16 (9.6) 6 (14.3) 1054 (48.0) 13 (14.3) 1 (3.1)
45-55 533 (25.5) 28 (16.8) 5 (11.9) 598 (27.2) 15 (16.5) 3 (9.4)
≥ 55 639 (30.5) 123 (73.7) 31 (73.8) 545 (24.8) 63 (69.2) 28 (87.5)
BMI
a (kg/m²) <
0.0001
< 18.5 56 (2.7) 10 (6.0) 1 (2.7) 125 (5.7) 9 (9.9) 3 (10.3)
18.5-24.9 1273
(60.9)
107 (64.1) 25 (67.6) 1500 (68.3) 48 (52.8) 18 (62.1)
25-29.9 ≥ 679 (32.5) 44 (26.4) 9 (24.3) 479 (21.8) 28 (30.8) 8 (27.6)
30 84 (4.0) 6 (3.6) 2 (5.4) 93 (4.2) 6 (6.6) 0 (0.0)
BMI
b (kg/m²) <
0.0001
< 18.5 56 (2.7)9 10 (6.0) 1 (2.4) 125 (5.7) 9 (9.9) 3 (9.4)
18.5-24 78 (46.8) 84 (50.3) 19 (45.2) 1279 (58.2) 39 (42.9) 16 (50.0)
24-27 708 (33.8) 57 (34.1) 15 (35.7) 528 (24.0) 25 (27.5) 9 (28.1)
≥ 27 350 (16.7) 16 (9.6) 7 (16.7) 265 (12.1) 18 (19.8) 4 (12.5)
Alcohol drinking 982 (46.9) 65 (38.9) 13 (31.0) 258 (11.7) 10 (11.0) 3 (9.4) <
0.0001
Smoking 1116
(53.4)
104 (62.3) 24 (57.1) 85 (3.9) 9 (9.9) 3 (9.4) <
0.0001
Betel nut chewing 660 (31.6) 57 (34.1) 16 (38.1) 61 (2.8) 5 (5.5) 2 (6.3) <
0.0001
Excercise 1076
(51.4)
90 (53.9) 23 (54.8) 1204 (54.8) 42 (46.2) 12 (37.5) 0.03
Education <
0.0001
Less than elementary
school
550 (26.3) 94 (56.3)53
(31.7) 20 (12.0)
24 (57.1)13
(31.0)5 (11.9)
811 (37.0)996 (45.4)388
(17.7)
69 (75.8)19 (20.9) 3
(3.3)
27 (84.4) 5 (15.6) 0
(0.0)
High school diploma 996 (47.6)
More than high school 546 (26.1)
Marital status <
0.0001
Married 1804
(86.3)
133 (79.6) 34 (81.0)1 (2.4)3
(7.1)4 (9.5)
1780 (81.0) 87 (4.0)
216 (9.8) 114 (5.2)
49 (53.9) 4 (4.4) 37
(40.7) 1 (1.1)
15 (46.9) 1 (3.1)16
(50.0) 0 (0.0)
Divorced or separated 54 (2.5) 4 (2.4)
Widower or widow/Living
together Single
60 (2.8)
174 (8.4)
16 (9.6)
14 (8.4)
Income <
0.0001
No income 228 (10.9) 44 (26.5) 10 (23.8) 760 (34.7) 47 (51.7) 19 (59.4)
Less than 10,000 NTD 197 (9.5) 33 (19.9) 9 (21.4) 263 (12.0) 27 (29.7) 12 (37.5)
10,000-40,000 NTD 888 (42.6) 63 (38.0) 18 (42.9) 886 (40.5) 14 (15.4) 1 (3.1)
More than 40,000 NTD 772 (37.0) 26 (15.7) 5 (11.9) 281 (12.8) 3 (3.3) 0 (0.0)
Self-reported CVD 277 (13.3) 47 (28.1) 19 (45.2) 290 (13.2) 36 (40.0) 18 (58.1) 0.9667
MetS 467 (22.3) 58 (34.7) 24 (57.1) 347 (15.8) 39 (42.9) 20 (62.5) <
0.0001
High WC 702 (33.6) 64 (38.3) 21 (50.0) 742 (33.8) 56 (61.5) 25 (78.1) 0.88
AH 596 (28.5) 94 (56.3) 32 (76.2) 422 (19.2) 50 (55.0) 20 (62.5) <
0.0001
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DM 188 (9.0) 35 (21.0) 16 (38.1) 147 (6.7) 22 (24.2) 11 (34.4)
HighTG 464 (22.2) 35 (21.0) 13 (31.0) 241 (11.0) 20 (22.0) 11 (34.4) <
0.0001
Low HDL-C 479 (22.9) 50 (29.9) 15 (35.7) 522 (23.8) 25 (27.5) 17 (53.1) 0.50
a: BMI classification according to the recommended standard of the WHO
b: BMI classification according to the recommended standard of the Taiwan
Department of Health
c: Significance level of two sample t-test or chi-squared test for the difference in gender
1BMI, body mass index; DM, diabetes mellitus; AH, arterial hypertension; HDL-C, high-density lipoprotein cholesterol; MetS, metabolic syndrome; NTD, New
Taiwan Dollar; TG, triglycerides; WC, waist circumference
2Central obesity was defined as WC ≥ 90 cm in men and ≥ 80 cm in women; AH was defined as an average SBP of ≥ 140 mmHg, DBP of ≥ 90 mmHg, or
treatment for previously diagnosed AH; DM was defined as a FPG ≥ 126 mg/dL (7 mmol/L) or use of insulin or other hypoglycemic agents; High TG was defined
as a serum triacylglycerol concentration ≥ 200 mg/dL (2.26 mmol/L); Low HDL-C was defined as a HDL-C < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL
(1.29 mmol/L) in women; The (modified) NCEP MetS was defined as having at least three of the following: (1) WC ≥ 90 cm in men and ≥ 80 cm in women; (2)
SBP ≥ 130 mmHg, DBP ≥ 85 mmHg, or self-reported treatment with antihypertensive medications; (3) FPG ≥ 110 mg/dL (6.1 mmol/L) or use of insulin or
hypoglycemic agents; (4) serum TG ≥ 150 mg/dL (1.7 mmol/L); (5) low HDL-C
Figure 1 Prevalence of MetS with age stratification (30-39, 40-49, 50-59, and ≥ 60). The shaded areas denote the corresponding
proportions of CVD-related deaths. MetS, metabolic syndrome.
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All-cause mortality
Death (%) (N = 167) Crude HR
(95% CI)
Adj HR†
(95% CI) ‡
p-value PAR (%)
(95% CI) ‡
Death (%) (N = 32) Crude HR
(95% CI)
Adj HR†
(95% CI) ‡
p-value PAR (%)
(95% CI) ‡
MetS 24 (57.1) 4.74 (2.42-9.28) 3.19 (1.55-7.58) 0.001* 39.2 (15.4-62.5) 20 (62.5) 9.24 (4.59-21.0) 3.45 (1.67-8.83) 0.003* 44.4 (18.7-69.8)
High WC 21 (50.0) 1.98 (1.05-3.69) 1.27 (0.57-2.66) 0.52 10.7 (1.4-40.6) 25 (78.1) 7.14 (3.38-24.3) 3.78 (1.79-13.6) 0.008* 57.5 (29.3-84.3)
AH 32 (76.2) 8.45 (4.19-20.0) 4.07 (1.84-9.98) 0.0005* 57.5 (28.6-79.6) 20 (62.5) 7.33 (3.54-16.4) 2.20 (1.03-5.50) 0.05* 34.1 (6.7-64.5)
DM 16 (38.1) 6.56 (3.29-12.9) 3.39 (1.51-8.61) 0.0004* 26.8 (8.3-48.5) 11 (34.4) 7.81 (3.52-16.6) 2.38 (0.98-5.70) 0.04* 19.9 (3.4-42.3)
High TG 13 (30.9) 1.56 (0.70-2.85) 1.29 (0.55-2.74) 0.47 6.9 (0.5-29.1) 11 (34.4) 4.34 (1.71-9.31) 1.97 (0.77-5.26) 0.10 16.9 (2.1-41.3)
Low HDL-C 15 (35.7) 1.89 (0.92-3.55) 2.07 (0.88-4.63) 0.03* 18.4 (3.0-38.9) 17 (53.1) 3.66 (1.81-7.90) 2.69 (1.25-6.51) 0.008* 33.4 (9.0-59.7)
†: Models were adjusted by age strata, CAD, stroke, BMI category, alcohol drinking, smoking, betel nut chewing, exercise, and income
‡: The 95% confidence interval (CI) obtained by taking the 2.5 and 97.5 percentiles of the recalculated PARs among one thousand bootstrapped datasets
#: CVD-related mortality (ICD-9th revision codes 240-279 and 390-459)
§: N/A: Not available. The adjusted HR was less than 1, yielding a negative corresponding PAR
*: p-value < 0.05 for the adjusted HR
BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; DM, diabetes mellitus; AH, arterial hypertension; HDL-C, high- density lipoprotein cholesterol; HR, hazard ratio;
MetS, metabolic syndrome; PAR, population attributable risk; TG, triglycerides; WC, waist circumference
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an alarmingly high PAR for all-cause mortality due to
cancer (3 out of 3).
The PARs of metabolic disorder for all-cause and CVD-
related mortality are shown in Table 2 for the single MetS
component without adjusting for other disorders. To
assess the effects of the other variables, Figure 3 displays
the PARs of MetS and its components after adjusting for
the other 4 components, which were quite similar to those
in Table 2. The PARs of AH were high in men and
women, similar to the levels observed with DM and low
HDL-C. However, central obesity had an alarmingly high
PAR in women, whereas it was not significant in men.
Table 3 compares the effect of metabolic disorders on
all-cause and CVD-related mortality in women accord-
ing to menopausal status, as determined by peri-meno-
pausal (aged 45-55 years old) or post-menopausal (≥ 55
years old) [25,26]. Because there were very few cases of
all-cause and CVD-related mortality for peri-menopau-
sal women (n = 15 and 3, respectively), none of the risk
factors were significantly associated. However, for post-
menopausal women, MetS, AH, and DM were signifi-
cantly associated with all-cause mortality (HRs 1.89,
2.14, and 1.99, respectively; PARs 19.5%, 33.2%, and
11.8%, respectively). The associations MetS, high WC,
DM, and low HDL-C and CVD-related mortality were
even stronger in the same age group, with HRs of 2.95,
3.38, 2.78, and 2.51, respectively, and PARs of 42.5%,
47.8%, 22.8%, and 24.5%, respectively.
To further investigate the gender disparity in central
obesity and hypertension, a log-rank test was applied to
test for differences between high WC = 1 and 0 (h-WC
= 1 and 0) and AH (AH = 1 and 0) for subjects aged ≥
55 years old who had relatively healthy lifestyles (non-
smoking, non-alcohol drinking, and non-betel nut chew-
ing) which included 190 men and 479 women. The
Kaplan-Meier curves showed that, while the group dif-
ference for high WC was not significant in men (p =
0.49), the association was significant in women (p =
0.04) (Figure 4a). In contrast, AH was highly significant
in men (p = 0.003), whereas it was not significant in
women (p = 0.09) (Figure 4b).
Figure 2 Metabolic disorder-specific PARs stratified by gender and age groups (smoking for men was included as a risk factor) for all-
cause mortality: a. Men; b. Women. AH, arterial hypertension; DM, diabetes mellitus; h-TG, high triglycerides; h-WC, high waist circumference; l-
HDL-C, low high-density lipoprotein cholesterol; MetS, metabolic syndrome; PAR, population attributable risk.
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nents, it is an important risk factor for CVD. The HRs
of smoking, adjusting for the components of MetS, for
all-cause and CVD-related mortalities were 1.27 and
0.89, respectively. When stratified by age (30-45, 45-55,
and ≥ 55 years old), the HRs for all-cause mortality in
men were 2.16, 0.84, and 1.23, respectively. However,
none of the HRs had a significant p-value. The HRs of
smoking for women is not presented here because of
the much smaller smoking rate in women than in men.
Discussion
Our study provides strong evidence that AH in men and
abdominal obesity in women represented the greatest
population attributable risks for CVD-related mortality
within an 8-year follow-up in Taiwan. The associations
between MetS and mortality confirmed the findings of
previous studies [6,8,10,11]. However, the attributable
risk of each independent MetS component varied with
age and gender. Although the prevalence of MetS was
higher in men than in women (22.3% vs. 15.8%), the HR
was marginally significant and had a smaller PAR for
all-cause mortality (11.6% vs. 18.6%). In contrast to the
significant associations observed for AH in women, AH,
DM, and low HDL-C were all significant in men. The
associations were similar for CVD-related mortality,
with approximately 40% of the deaths attributable to
MetS (for PAR, 39.2% in men and 44.4% in women).
A strong gender disparity was found in our study. AH
had the highest PAR in men (57.5%), and high WC had
the highest PAR in women (57.5%). Central obesity in
men was not significantly associated with mortality. This
finding was different from the results of other studies
[2,3,7,27]. One possible explanation is that, overall, gen-
der differences for biological susceptibility to athero-
sclerosis and risky health-related behaviors, including
Figure 3 PARs of MetS and its components after adjusting for the other 4 components. (The PARs of h-WC and h-TG in men were not
shown because of negative values resulting from non-significant adjusted HRs.) AH, arterial hypertension; DM, diabetes mellitus; h-TG, high
triglycerides; h-WC, high waist circumference; l-HDL-C, low high-density lipoprotein cholesterol; MetS, metabolic syndrome; PAR, population
attributable risk.
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Page 8 of 12poor food choices, made this disparity significant
between men and women [28]. This may be partly due
to an increased tendency of left ventricular hypertrophy
in men as well as higher smoking rates and alcohol con-
sumption among men [29].
While smoking is not a metabolic disorder, it is the
most important risk factor for a coronary event [30]. As
s h o w ni nF i g u r e2 ,y o u n g e rm e na g e d3 0 - 4 5h a ds t r i k -
ingly high PARs for all-cause mortality. This finding is
consistent with studies suggesting that young smokers
have higher PARs for coronary heart disease [4,31]. In
the Framingham Heart Study, it was found that the com-
peting risk of death from other smoking-related causes
shortened median survival by 5 years [32]. A possible link
of the elevated PARs of smoking and the metabolic risk
factors in younger men were deaths related to cancer or
unrecognized cardiac events [33]. The contribution of
smoking to the PAR might be expected to operate in part
through its probable role in the development of abdom-
inal obesity [34,35]. Therefore, it is somewhat surprising,
given the high prevalence of smoking in Taiwanese men,
that the PAR is greatest in young men. Perhaps, there are
delayed and negated effects of smoking on mortality.
This result may provide some insight into why northeast
Asian men may achieve relative longevity despite their
high rates of cigarette smoking [34-40].
Post-menopausal women are also more prone to cen-
tral or android obesity, which is more closely associated
with the development of type 2 diabetes and increased
CVD mortality [14]. This association is most likely due
to the decreased levels of circulating estrogen and
altered lipid levels after menopause, which increased the
risk of mortality over the subsequent 2 years [13,41].
The significant association between MetS and mortality
in men was inconsistent with the conclusion of Lin et
al. [11], though the association in post-menopausal
women was consistent. Furthermore, our results showed
t h a tt h er i s kr o s em o r eq u i c k ly within the first 8 years
rather than at a follow-up period of 10 to 15 years.
Another consideration is that the assessment of abdom-
inal obesity in northeast Asian may not be the same as
in Caucasians [35-37].
In contrast to older women who had higher PARs for
MetS and other metabolic risk factors, younger men
Table 3 Adjusted HRs and PARs of metabolic disorders for all-cause and CVD-related mortality in women stratified by
menopausal status (N = 1143)
All-cause mortality
Peri-menopausal Post-menopausal
45 ≤ Age < 55 Age ≥ 55
Death (%)(n = 15) Adj HR†
(95% CI) ‡
PAR (%)
(95% CI)‡
Death
(%)(n = 63)
Adj HR†
(95% CI) ‡
PAR (%)
(95% CI)‡
MetS 4 (26.7) 1.70 (0.33-4.86) 13.4 (1.6-35.3) 35 (55.6) 1.89 (1.05-3.59)* 19.5 (4.1-32.9)
High WC 8 (53.3) 2.33 (0.66-10.90) 26.5 (3.2-51.6) 46 (73.0) 1.48 (0.79-3.44) 16.6 (1.5-39.4)
AH 6 (40.0) 2.48 (0.64-9.38) 25.0 (3.0-47.1) 42 (66.7) 2.14 (1.21-4.27)* 33.2 (11.6-50.6)
DM 0 (0.0) N/A§ N/A§ 22 (34.9) 1.99 (1.02-3.64)* 11.8 (2.18-20.0)
High TG 3 (20.0) 1.64 (0-4.70) 9.1 (0.7-26.7) 17 (27.0) 1.20 (0.64-2.31) 3.2 (0.3-13.5)
Low HDL-C 2 (13.3) 0.61 (0-2.21) N/A§ 21 (33.3) 1.12 (0.58-1.97) 2.9 (0.4-16.2)
CVD-related mortality
Peri-menopausal Post-menopausal
45 ≤ Age < 55 Age ≥ 55
Death (%)
(n = 3)
Adj HR†
(95% CI) ‡
PAR (%)
(95% CI)‡
Death (%)
(n = 28)
Adj HR†
(95% CI) ‡
PAR (%)
(95% CI)‡
MetS 2 (66.7) 6.21 (N/A§) 41.9 (4.3-86.8) 18 (64.3) 2.95 (1.39-8.71)* 42.5 (19.4-64.7)
High WC 3 (100) N/A§ N/A§ 22 (78.6) 3.38 (1.52-15.1)* 47.8 (21.2-71.3)
AH 2 (66.7) 6.44 (N/A§) 52.8 (4.0-100) 18 (64.3) 1.93 (0.88-5.50) 36.0 (6.37-68.1)
DM 0 N/A§ N/A§ 11 (39.3) 2.78 (1.16-7.31)* 22.8 (4.99-38.6)
High TG 2 (66.7) 11.5 (N/A§) 45.6 (11.2-85.7) 9 (32.1) 1.65 (0.51-4.88) 11.4 (1.4-30.4)
Low HDL-C 1 (33.3) 3.96 (N/A§) 28.0 (2.99-75.0) 15 (53.6) 2.51 (1.06-6.11)* 24.5 (5.22-42.3)
†: CAD, stroke, BMI, alcohol drinking, smoking, betel nut chewing, exercise, and income were adjusted for in the model.
‡: The 95% CI obtained by taking the 2.5 and 97.5 percentiles of the recalculated PARs among one thousand bootstrapped datasets.
§: N/A: not available. The adjusted HR was less than 1 due to small number of observations, yielding a negative corresponding PAR.
#: CVD-related mortality (ICD-9
th revision codes 250, 390-398, and 401-441).
BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; DM, diabetes mellitus; AH, arterial hypertension; HDL-C,
high-density lipoprotein cholesterol; HR, hazard ratio; MetS, metabolic syndrome; PAR, population attributable risk; TG, triglycerides; WC, waist circumference
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Page 9 of 12aged 30-45 also had strikingly high PARs for AH, DM,
elevated TG and low HDL-C for all-cause mortality
(Figure 2). This result may be due to the “female advan-
tage” in the pre-menopausal women compared to age-
matched men for metabolic diseases [14,28]. Younger
m e nw i t hD Mo rl o wH D L - Ca l s oh a dh i g h e rP A R s
than the other age groups for CVD-related mortality.
There were some limitations with this study. First,
due to the 8-year follow-up period, the number of
deaths associated with different risk factors may not
have been large enough to yield reliable HR and PAR
estimates with the desired 95% CI. However, because
the subjects were sampled in a manner proportional to
the population size, the causal relationship should be
unbiased for the study population. Moreover, for
almost all of the significant risk factors, the boot-
strapped 95% CIs corresponding to the PAR estimates
were within reasonable ranges and had positive lower
bounds. Thus, the findings and inferences that were
made should be legitimate.
Figure 4 Kaplan-Meier curves are illustrated for CVD-related morality in subjects 55 years or older both with and without central
obesity or hypertension in men (left column) and women (right column). a. Central obesity (h-WC = 1, dotted line; h-WC = 0, solid line); b.
Arterial hypertension (AH = 1, dotted line; AH = 0, solid line). All the subjects who smoked, drank alcohol, or chewed betel nut were excluded.
AH, arterial hypertension; CVD, cardiovascular disease; h-WC, high waist circumference.
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Page 10 of 12Second, the HRs and PARs of the metabolic disorders
given in Tables 2 and 3 were obtained without adjusting
for other MetS components. It is not clear what the
PARs would be in the presence of a single metabolic
disorder or with various combinations of these cardio-
vascular risk factors. Because of sample size limitations,
the current dataset could not provide such information.
Further analyses using a larger cohort to assess the cor-
responding PARs are needed. However, as shown in Fig-
ure 3, the PARs of MetS and its components, adjusting
for the other 4 components, were quite similar to those
shown in Table 2.
Third, we classified the menopausal status of women
with a cutoff of 55 years of age, rather than biomarker
measurements such as serum FSH (follicle-stimulating
hormone, a hormone synthesized and secreted by gonado-
trophs of the anterior pituitary gland, which regulates
development, growth, pubertal maturation, and reproduc-
tion) [11]. Misclassifications may have occurred due to
this stratification. The number of peri-menopausal women
with CVD-related deaths was very small (n = 3), which
may be insufficient to yield any valid statistical inference
for this subpopulation. Additionally, there was little infor-
mation on the rate of use of estrogen or hormone replace-
ment therapy among the study subjects, which may have
altered the CVD risk and mortality rates [13].
Conclusions
In summary, the adjusted PARs show that MetS has a
greater relevance for CVD-related mortality than for all-
cause mortality over an 8-year follow-up period. How-
ever, men with AH and post-menopausal women with
central obesity accounted for most of the PAR in CVD-
related mortality. Likewise, for all-cause mortality, the
highest PARs were for AH in men and women with
central obesity. Younger men and older women had
higher PARs for all-cause mortality for the various MetS
components. The gender differences may reflect the
higher prevalence of smoking among men, although we
made appropriate adjustments for this variable in our
analysis. Focusing on MetS and AH and their associa-
tions with all-cause and CVD-related mortality without
regard to age or gender may have significant policy
implications. Moreover, the PARs of approximately 30%
for CVD mortality due to diabetes in men and women
and due to low HDL-C in post-menopausal women
deserve special attention. However, these recommenda-
tions may not be as applicable to MetS or its compo-
nents when morbidity or non-CVD mortality is
considered. Nevertheless, these findings warrant a re-
evaluation of the priorities for intervention at the ear-
liest phase in the development of risk factors for prema-
ture death.
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